scholarly journals Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome

2014 ◽  
Vol 49 (11) ◽  
pp. 1360-1365 ◽  
Author(s):  
M J Lechowicz ◽  
H M Lazarus ◽  
J Carreras ◽  
G G Laport ◽  
C S Cutler ◽  
...  
Keyword(s):  
Cell Transplantation ◽  
Mycosis Fungoides ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
Sézary Syndrome ◽  
Sezary Syndrome

scholarly journals Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide for Sézary Syndrome

2020 ◽  
Vol 13 (2) ◽  
pp. 1053-1058
Author(s):  
Madoka Kanda-Kato ◽  
Satoshi Yoshioka ◽  
Takayuki Ishikawa
Keyword(s):  
Cell Transplantation ◽  
Bacterial Infections ◽  
Hematopoietic Cell Transplantation ◽  
Cord Blood Transplantation ◽  
Infectious Complications ◽  
Hematopoietic Cell ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Blood Transplantation ◽  
Unrelated Cord Blood

Patients with advanced-stage mycosis fungoides (MF) and Sézary syndrome (SS) have a poor prognosis. Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment option; however, since most patients with MF/SS are elderly, they often have difficulty in finding HLA-matched donors. In recent years, HCT from HLA-haploidentical donors (haplo-HCT) using posttransplant cyclophosphamide (PTCy) as graft-versus-host disease prophylaxis has been conducted for patients without HLA-matched donors. Infectious complications, particularly cutaneous bacterial infections, are common among patients with MF/SS. The lower incidence of severe infectious complications after haplo-HCT than after an unrelated cord blood transplantation could lead to lower transplant-related mortality. Here, we report on a patient with SS who was treated successfully with haplo-HCT with PTCy. The patient has remained in complete remission for more than 24 months.

Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and Sézary Syndrome: A Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

2010 ◽  
Vol 28 (29) ◽  
pp. 4492-4499 ◽  
Author(s):  
Rafael F. Duarte ◽  
Carmen Canals ◽  
Francesco Onida ◽  
Ian H. Gabriel ◽  
Reyes Arranz ◽  
...  
Keyword(s):  
Cell Transplantation ◽  
Mycosis Fungoides ◽  
Marrow Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Allogeneic Transplantation ◽  
Hematopoietic Cell ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
Blood And Marrow Transplantation ◽  
Advanced Phase ◽  
European Group

PurposeTo analyze the outcome of allogeneic transplantation for mycosis fungoides and Sézary syndrome (MF/SS) in terms of nonrelapse mortality (NRM), relapse/progression (REL), progression-free survival (PFS), and overall survival (OS) and to identify factors associated with the outcome.Patient and MethodsSixty patients with MF (n = 36) and SS (n = 24) who received a first allogeneic hematopoietic cell transplantation (HCT) from a matched related (mRD; n = 45) or unrelated donor (mUD; n = 15) between 1997 and 2007 and who were registered in the European Group for Blood and Marrow Transplantation database were analyzed: 37 men and 23 women, median age 46.5 years (range, 22 to 66 years). Forty-four patients had TNM stage IV, and 40 patients were at advanced phase at transplantation. Forty-four patients received reduced-intensity conditioning (RIC) regimens, and 25 underwent T-cell depletion (TCD).ResultsAllogeneic transplantation in MF/SS offers an estimated OS of 66% at 1 year and 54% at 3 years, primarily driven by donor type, disease phase, and type of conditioning. RIC decreased NRM (relative risk [RR] = 4.7; P = .008) without increasing REL, leading to a higher OS (RR = 2.8; P = .03). Advanced-phase disease increases REL (RR = 3.0; P = .03) and reduces PFS (RR = 4.4; P = .002) and OS (RR = 3.5; P = .023). Recipients of mRD allogeneic HCT had better PFS (RR = 2.7; P = .006) and OS (RR = 4.0; P = .001) than their mUD counterparts. The risk of REL increases with TCD (RR = 3.2; P = .005). Some patients who experience relapse can successfully undergo rescue treatment with donor lymphocyte infusions.ConclusionAllogeneic transplantation is a valid therapeutic alternative for high-risk patients with advanced-stage MF/SS. Our data also suggest the existence of a clinically relevant graft-versus-lymphoma effect in MF/SS.

Impact of Palifermin on Transplant Outcomes in Children and Adolescents Undergoing Allogeneic Hematopoietic Cell Transplantation

2020 ◽  
Vol 40 (11) ◽  
pp. 6531-6537
Author(s):  
KRZYSZTOF CZYŻEWSKI ◽  
ROBERT DĘBSKI ◽  
NATALIA BARTOSZEWICZ ◽  
EWA DEMIDOWICZ ◽  
MONIKA RICHERT-PRZYGOŃSKA ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
Transplant Outcomes
Sign in / Sign up

Export Citation Format

Share Document